Sunshine Biopharma Inc (SBFM)

[TraderAI]

I can see a couple problems with this March 2022 presentation, when at least one institutional investor bailed. No idea why any bailed but the timing is interesting and 4 up and bailed. Sold everything.


Sunshine Biopharma Presentation – March 2022

https://investors.sunshinebiopharma.com/assets/Sunshine%20Biopharma_Presentation%2020220308_Updated_FINAL%20(2).pdf

Look at Upcoming Milestones. I realized Steve Slilaty is not a medical doctor.

Only a doctor of philosophy. That’s a 3 or 4 year course.

Specifically this bothers me:

Upcoming Milestones
Adva-27a Drug Development Program:
? GMP Manufacturing (5 Kilograms)
? IND-Enabling Studies
? Filing of IND Application (“Fast-Track” anticipated)
? Phase I Clinical Trials (Pancreatic Cancer, Jewish General Hospital)
Antiviral Program:
? Efficacy Studies in Coronavirus Infected Mice
? GMP Manufacturing (5 Kilograms)
? Filing of IND Application (“Fast-Track” anticipated)
? Phase I Clinical Trials (University of Georgia Affiliate Hospital)
Supplements:
? Large-Scale Marketing
? Expansion beyond US and Canada

Look also at R&D Pipeline. Adva-27a worth in excess of 1 billion and time to Phase 1: 9-18mos. Covid same thing, but multi-billion. This is great, but not much has happened except a mice and some research studies in all these years.

How many times are they going anticipate filing? They’ve put out several PRs, the first around mid 2020 about FDA fast track and patent priority filing.

And the forward looking statement? Maybe that’s regular boiler plate legalese, but it says this at the very top:

Sunshine Biopharma Inc. does not intend, and does not assume any obligation, to update these “forward-looking statements” except as required by law. These “forward-looking statements” involve risks and uncertainties relating to, among other things, results of and sale activities, uninsured risks, regulatory changes, availability of production facilities, timeliness of government approvals and the granting of permits and licenses, changes in prices, actual operating and financial performance of facilities, equipment and processes relative to specifications and expectations. Actual results may differ materially from those expressed or implied by such “forward-looking statements.”